TY - JOUR
T1 - Methotrexate in chronic active ulcerative colitis
T2 - A double-blind, randomized, Israeli multicenter trial
AU - Oren, R.
AU - Arber, N.
AU - Odes, S.
AU - Moshkowitz, M.
AU - Keter, D.
AU - Pomeranz, I.
AU - Ron, Y.
AU - Reisfeld, I.
AU - Broide, E.
AU - Lavy, A.
AU - Fich, A.
AU - Eliakim, R.
AU - Patz, J.
AU - Bardan, E.
AU - Villa, Y.
AU - Gilat, T.
PY - 1996
Y1 - 1996
N2 - Background and Aims: Uncontrolled studies have suggested that methotrexate may be effective in patients with active ulcerative colitis. The aim of this study was to evaluate the effectiveness of oral methotrexate in chronic steroid-dependent ulcerative colitis in a randomized, double-blind multicenter trial. Methods: Patients with active ulcerative colitis who have received steroids and/or immunosuppressives for at least 4 months during the preceding 12 months with a current Mayo Clinic score of ≥7 were included in the study. Methotrexate (12.5 mg) or placebo was added to their treatment once weekly for 9 months. Results: Sixty-seven patients were included (methotrexate, 30 patients; placebo, 37 patients). The proportion of patients entering first remission (methotrexate, 46.7%; placebo, 48.6%), the time to reach first remission (methotrexate, 4.1 ± 1.9 months; placebo, 3.4 ± 1.7 months), as well as the proportions of patients having a relapse after first remission (methotrexate, 64.3%; placebo, 44.4%) were not significantly different between the two groups. The mean Mayo Clinic score, the mean monthly steroid dose, and the proportion of abnormal laboratory results during the study were also similar. Conclusions: Methotrexate at a weekly oral dose of 12.5 mg was not found to be better than placebo in the induction or maintenance of remission in patients with chronic active ulcerative colitis.
AB - Background and Aims: Uncontrolled studies have suggested that methotrexate may be effective in patients with active ulcerative colitis. The aim of this study was to evaluate the effectiveness of oral methotrexate in chronic steroid-dependent ulcerative colitis in a randomized, double-blind multicenter trial. Methods: Patients with active ulcerative colitis who have received steroids and/or immunosuppressives for at least 4 months during the preceding 12 months with a current Mayo Clinic score of ≥7 were included in the study. Methotrexate (12.5 mg) or placebo was added to their treatment once weekly for 9 months. Results: Sixty-seven patients were included (methotrexate, 30 patients; placebo, 37 patients). The proportion of patients entering first remission (methotrexate, 46.7%; placebo, 48.6%), the time to reach first remission (methotrexate, 4.1 ± 1.9 months; placebo, 3.4 ± 1.7 months), as well as the proportions of patients having a relapse after first remission (methotrexate, 64.3%; placebo, 44.4%) were not significantly different between the two groups. The mean Mayo Clinic score, the mean monthly steroid dose, and the proportion of abnormal laboratory results during the study were also similar. Conclusions: Methotrexate at a weekly oral dose of 12.5 mg was not found to be better than placebo in the induction or maintenance of remission in patients with chronic active ulcerative colitis.
UR - http://www.scopus.com/inward/record.url?scp=9244264980&partnerID=8YFLogxK
U2 - 10.1053/gast.1996.v110.pm8613046
DO - 10.1053/gast.1996.v110.pm8613046
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:9244264980
SN - 0016-5085
VL - 110
SP - 1416
EP - 1421
JO - Gastroenterology
JF - Gastroenterology
IS - 5
ER -